Optimal Endometrial Preparation Protocols for Frozen-thawed Embryo Transfer Cycles by Maternal Age

Qizhen Zheng  
Shenzhen Zhongshan Urology Hospital, ART center

Hongzhan Zhang  
Shenzhen Zhongshan Urology Hospital, ART center

Shiru Xu  
Shenzhen Zhongshan Urology Hospital

Shan Xiao  
Shenzhen Zhongshan Urology Hospital

Xuejin Wang  
Shenzhen Zhongshan Urology Hospital

Meilan Mo  
Shenzhen Zhongshan Urology Hospital

Yong Zeng (✉ zengyong1966@gmail.com)  
Shenzhen Zhongshan Urology Hospital  https://orcid.org/0000-0002-6264-283X

Research

Keywords: frozen-thawed embryo transfer, endometrial preparation protocol, live birth rate, early miscarriage rate, maternal age

DOI: https://doi.org/10.21203/rs.3.rs-113037/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: It is paramount to consider the appropriate preparation of the endometrium to receive the transferred embryos as the amount of frozen embryo transfer (FET) cycles is increasing worldwide. However, there remains lack of evidence about what is the most optimal protocol of endometrial preparation regarding pregnancy outcomes in different subgroup of infertile women. This retrospective cohort study was aim to explore the best endometrial preparation protocols among different maternal age groups.

Methods: A total of 16870 FET cycles were categorized into three groups based on endometrial preparation protocols: Natural cycle (NC n=3893), artificial cycles (AC, n=11459) and AC with pretreatment with GnRH-a (AC+GnRH-a, n=1518). Logistic regression was performed to investigate the independent effect of endometrial preparation protocols on IVF pregnancy outcomes. Subgroup analyses were conducted to evaluate the most optimal endometrial preparation protocols for different maternal age groups.

Results: In overall populations, after controlling for potential confounders, the incidence of live birth (NC as reference; AC: adjusted odds ratio (aOR) =0.840, 95%CI 0.774-0.912; AC+GnRHa: aOR=0.907, 95%CI 0.795-1.034) in NC was significantly higher than that of AC, while comparable to that of AC+GnRHa. The early miscarriage rate (AC: aOR=1.413, 95%CI 1.220-1.638; AC+GnRHa: aOR=1.537, 95%CI 1.232-1.919) was significantly lower in NC compared to either AC group. In younger women, the live birth rates (AC: aOR=0.894, 95%CI 0.799-1.001; AC+GnRHa: aOR=1.111, 95%CI 0.923-1.337) were comparable between the three groups, with a slightly higher in AC+GnRHa-a. Early miscarriage rate was only significantly lower in NC compared to that of AC without GnRH-a (aOR=1.452, 95%CI 1.159-1.820). While in older women, the incidence of live birth (AC: aOR=0.811, 95%CI 0.718-0.916; AC+GnRHa: aOR=0.760, 95%CI 0.626-0.923) was significantly higher, and early miscarriage (AC: aOR=1.358, 95%CI 1.114-1.655; AC+GnRHa: aOR=1.717, 95%CI 1.279-2.305) was significantly lower in NC compared to those of two AC groups.

Conclusions: NC protocol is associated with lower early miscarriage late in overall IVF population. There is a mild favor of AC+GnRH-a in younger women, while the priority of NC is remarkable in older women. Maternal age should be a considerable factor when determine endometrial preparation method for FET.

Introduction

Since the first report on successful pregnancy after frozen-thawed embryo transfer (FET) in 1983, the amount of FET has been increasing worldwide, particularly driven by the advanced vitrification technique allowing safe and efficient cryopreservation, storage and warming of embryos [1, 2]. Current evidence indicates that FET cycles not only produce non-inferior live birth rate to fresh cycles, but reduce multiple pregnancy rate by selecting single good-quality blastocyst for transfer, and minimize the risk of ovarian hyperstimulation syndrome [3–5]. Regardless, the optimal method of endometrial preparation remains a topic of ongoing debate.
The major endometrial preparation protocols can be generally classified into natural cycles (NC) and artificial cycles (AC). In NC, follicle development and ovulation are required to maintain the physiological hormonal milieu for endometrial growth and embryo implantation. Alternatively, in AC, this physiological process is overridden by the administration of exogenous estrogen and progesterone. AC with GnRH-a pretreatment is applied to minimize the risk of premature ovulation and prevent cycle cancelation [6], it was also reported to increase live birth in patients with adenomyosis [7, 8].

In clinical practice, AC is increasingly adopted as NC may not be possible in patients with ovulatory disorders. Additionally, AC provides a better control of FET timing and transfer, which is convenient for both patients and physicians. However, questions remain unanswered whether AC is equivalent to NC regarding pregnancy outcomes and safety, as several recent publications have reported a higher risk of hypertensive disorders in the absence of a corpus luteum [9–11]. In this study, we aim to compare pregnancy outcomes after different endometrial preparation protocols in FET cycles, and to explore the optimal protocols in different age groups.

Materials And Methods

Study Design and Population

This was a retrospective cohort study of women underwent IVF/ICSI treatment in our fertility center from January 2015 to June 2019. Excluding criteria included cycles with no viable embryos available for transfer or underwent Pre-implantation genetic diagnosis, and cycles in which transferred embryos came from different ovarian stimulation cycles, or mixed with cleavage and blastocyst stage embryos. The eligible cycles were classified into three groups according to the endometrial preparation protocols: natural cycle (NC), artificial cycle (AC) without GnRH-a, and AC with GnRH-a pretreatment (AC + GnRH-a).

Cryopreservation and thawing

Standard regimens for controlled ovarian stimulation (COH) were applied by clinicians in our center based on the individual ovarian reserve and response, including long agonist protocols, antagonist protocols, and clomiphene-based mild stimulation protocols. Ovulation was triggered with either human chorionic gonadotropin (hCG, Lizhu; Zhuhai, China) 6 500 – 10 000 IU or a single subcutaneous bolus of triptorelin (Diphereline; Ipsen, France) 0.2 mg, oocyte retrieval was performed 34–36 hours after.

Insemination of mature oocytes was performed by conventional IVF or ICSI according to the sperm parameters. Details on embryo culture, vitrification, thawing and transfer procedures have been described in our previous studies [12, 13]. Embryos on Day 3 were graded according to the morphology criteria [14]. Good and fair embryos were cryopreserved or undergoing blastocyst culture. The Gardner grading system was used to evaluate the blastocyst quality [15]. Only blastocysts better than grade 3CC were selected for vitrification. The laboratory procedures were performed by well-trained embryologists, each with over
5 years of laboratory experience. There were no substantial changes of laboratory practices over the course of study.

**Endometrial preparation protocols**

The patients were allocated to different endometrial preparation protocols based on the experience of the clinician and patients’ characteristic. NC was chosen if the patient had regular menses or refused to take medication, AC with or without GnRH-a was selected in patients with irregular menses, or who lived at considerable distance and did not wish to be frequently monitored.

**NC:** Surveillance of the cycle was done from day 8–10 of the cycle with vaginal ultrasound until the leading follicle was $\geq 18$ mm or the urine LH surge was observed. Ovulation may occur spontaneously or triggered by 10 000 IU hCG (Choriomon, IBSA, Lugano, Switzerland). Oral administration of 20 mg progesterone twice daily was prescribed for 3/5 days before FET of cleavage/blasto cyst stage embryo.

**AC:** endometrial preparation was started from day 2–3 of menstrual cycle with daily administration of 4–8 mg oral estradiol valerate (Progynova; Bayer, Germany) for 15 days. Intramuscular administration of 60 mg progesterone daily (ZheJiang XianJu Pharmaceuticals, China) was prescribed for 4/6 days before FET of cleavage/blastocyst stage embryo.

**AC + GnRH-a:** The injection of leuproleline acetate (Diphereline; Ipsen, France) 3.75 mg i.m., was administered during the mid-luteal phase of the menstrual cycle, twenty-nine days later the hormone replacing protocol as in AC was started.

In all three protocols, serum estradiol (E2), progesterone (P) levels, and endometrium thickness were measured on hCG day in NC or on progesterone day in AC. One-two blastocysts or 1–3 cleavage stage embryos were transferred under ultrasound guidance. From the day of embryo transfer. Luteal support was prescribed with 20 mg progestin tablets (Duphaston; Abbott, Netherlands) orally twice daily and 90 mg progestin gel (Crinone; Merck, Germany) vaginally daily until a serum beta hCG assay was performed 11 (if blastocyst was transferred) or 13 days (if cleavage embryo was transferred) after FET. Luteal support was continued to 12 weeks of gestation if pregnancy was resulted.

**Definition of clinical outcomes**

Clinical pregnancy was defined as the observation of at least one gestational sac on transvaginal ultrasound at 6–7 weeks of gestation. Ongoing pregnancy was defined as a pregnancy proceeding beyond 12 weeks of gestation. Early miscarriage was defined as the pregnancy loss before 12 weeks of gestation. Live birth was defined as an infant born alive after 28 weeks of gestation.

**Statistical analysis**
The demographic characteristics and clinical outcomes were described as mean ± SD for continuous variables and as frequency with proportion for categorical variables. The differences between groups were tested using the ANOVA test for continuous variables and the Pearson's chi-square test for categorical variables. Multivariable logistic regression was performed to investigate the effect of endometrial preparation protocol on pregnancy outcome after controlling for potential confounders, endometrial preparation method group was included as a categorical variable, and NC was selected as the reference. The results were reported as adjusted odds ratios (aORs) with 95% CIs. Subgroup analysis stratified by maternal age (<35 year or ≥ 35 year) was performed to explore the most optimal endometrial preparation protocol for different age groups. All statistical analyses were performed by using the two-sided 5% level of significance in the statistical package Stata, Version 19 (StataCorp, College Station, TX, USA).

**Results**

Totally there were 16870 FET cycles included in the study: 3893 NC cycles, 11459 AC cycles without GnRH-a and 1518 AC cycles with GnRH-a pretreatment. The demographic data were shown in Table I. It is of note that the maternal age in the Group of AC cycles without GnRH-a was about 2 years younger than the other two groups. When stratified by maternal age, there were 9341 cycles with younger age (<35 years), and 7529 cycles with advanced age (≥ 35 years).
|                          | NC          | AC          | AC+GnRH-a   | \( P \) |
|--------------------------|-------------|-------------|-------------|--------|
| cycles (n)               | 3893        | 11459       | 1518        |        |
| maternal age (y)         | 35.15±4.57  | 33.51±4.77  | 35.22±4.97  | 0.000  |
| cycle rank (n)           | 1.83±1.10   | 1.58±0.95   | 1.85±1.19   | 0.000  |
| BMI (kg/m\(^2\))        | 21.28±2.81  | 21.61±3.07  | 21.77±3.28  | 0.000  |
| Nulliparity (%)          | 1595(40.97) | 5105(44.55) | 656(43.21)  | 0.000  |
| Duration of infertility (y) | 3.67±3.02  | 3.57±2.80   | 4.12±3.31   | 0.000  |
| Indication of treatment, n (%) |          |             |             | 0.000  |
| Pelvic                   | 1379(35.42) | 3896(34.00) | 495(32.61)  |        |
| Ovulatory disorder       | 38(0.98)    | 1085(9.47)  | 100(6.59)   |        |
| Endometriosis            | 331(8.50)   | 709(6.19)   | 234(15.42)  |        |
| Immunology               | 60(1.54)    | 148(1.29)   | 13(0.86)    |        |
| Male                     | 623(16.00)  | 1596(13.93) | 181(11.92)  |        |
| Combined                 | 568(14.59)  | 1640(14.31) | 215(14.16)  |        |
| Idiopathic               | 894(22.96)  | 2385(20.81) | 280(18.45)  |        |
| Fertilization method, n (%) |          |             |             | 0.000  |
| IVF                      | 2640(67.81) | 8139(71.03) | 1063(70.03) |        |
| ICSI                     | 1235(31.72) | 3211(28.02) | 444(29.25)  |        |
| IVF+ICSI                 | 18(0.46)    | 109(0.95)   | 11(0.72)    |        |
| Embryo stage, n (%)      |            |             |             | 0.000  |
| D3                       | 1484(38.12) | 3537(30.87) | 731(48.16)  |        |
| D5                       | 2409(61.88) | 7922(69.13) | 787(51.84)  |        |
| Number of embryos transferred (n) | 1.70±0.63 | 1.73±0.63   | 1.91±0.65   | 0.000  |
| Number of top embryos (n) | 1.32±0.88  | 1.36±0.88   | 1.52±0.94   | 0.000  |
| Endometrium thickness (mm) | 9.90±1.74  | 9.42±1.54   | 9.86±1.74   | 0.000  |
| E2 (pg/ml)               | 401.27±360.76 | 440.87±491.23 | 428.81±527.90 | 0.000  |
| P (ng/ml)                | 0.56±0.36  | 0.29±0.21   | 0.27±0.21   | 0.000  |
NC, natural cycle; AC, artificial cycle; GnRH-a, gonadotropin releasing hormone agonist; BMI, body mass index; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; E2, estrogen; P, progesterone

P<0.05 was considered as statistically significant

The IVF/ICSI pregnancy outcomes per FET cycle for the three groups in overall population are showed in Figure I. The results of logistic regression are shown in Table II. After controlling for potential confounders, the incidences of clinical pregnancy (NC as reference; AC: adjusted odds ratio (aOR) = 0.923, 95%CI 0.852–1.000; AC + GnRH-a: aOR = 1.008, 95%CI 0.855–1.110) were comparable between the three groups. The incidences of live birth (AC: aOR = 0.840, 95%CI 0.774–0.912; AC + GnRH-a: aOR = 0.907, 95%CI 0.795–1.034) and ongoing pregnancy (AC: aOR = 0.837, 95%CI 0.771–0.901; AC + GnRH-a: aOR = 0.891, 95%CI 0.782–1.016) in NC were significantly higher than that of AC, while comparable to that of AC + GnRH-a. The early miscarriage rate (AC: aOR = 1.413, 95%CI 1.220–1.638; AC + GnRH-a: aOR = 1.537, 95%CI 1.232–1.919) was significantly lower in NC compared to either AC group.

Table II
Crude and adjusted ORs of different endometrial preparation protocols in overall population.

|                         | NC     | AC     | P1    | AC+GnRH-a | P2    |
|-------------------------|--------|--------|-------|-----------|-------|
| **Clinical pregnancy rate** |        |        |       |           |       |
| Crude OR(95%CI)         | reference | 1.157(1.075,1.244) | 0.000 | 1.009(0.896,1.136) | 0.884 |
| Adjusted OR(95%CI)      | reference | 0.923(0.852,1.000) | 0.054 | 1.008(0.855,1.110) | 0.905 |
| **Ongoing pregnancy rate** |        |        |       |           |       |
| Crude OR(95%CI)         | reference | 1.068(0.992,1.149) | 0.082 | 0.906(0.802,1.022) | 0.108 |
| Adjusted OR(95%CI)      | reference | 0.837(0.771,0.901) | 0.000 | 0.891(0.782,1.016) | 0.085 |
| **Live birth rate**     |        |        |       |           |       |
| Crude OR(95%CI)         | reference | 1.057(0.981,1.138) | 0.145 | 0.911(0.806,1.029) | 0.133 |
| Adjusted OR(95%CI)      | reference | 0.840(0.774,0.912) | 0.000 | 0.907(0.795,1.034) | 0.144 |
| **Early miscarriage rate** |        |        |       |           |       |
| Crude OR(95%CI)         | reference | 1.198(1.042,1.376) | 0.011 | 1.451(1.173,1.796) | 0.001 |
| Adjusted OR(95%CI)      | reference | 1.413(1.220,1.638) | 0.000 | 1.537(1.232,1.919) | 0.000 |

NC, natural cycle; AC, artificial cycle; GnRH-a, gonadotropin releasing hormone agonist

P<0.05 was considered as statistically significant
The pregnancy outcomes stratified by maternal age are shown in Figure II. Logistic regression indicated that in younger women (Table III), the live birth (AC: aOR = 0.894, 95%CI 0.799–1.001; AC + GnRH-a: aOR = 1.111, 95%CI 0.923–1.337) and clinical pregnancy rates (AC: aOR = 0.976, 95%CI 0.870–1.095; AC + GnRH-a: aOR = 1.197, 95%CI 0.988–1.450) were comparable between the three groups, although slightly higher in AC + GnRH-a. Ongoing pregnancy rate (AC: aOR = 0.889, 95%CI 0.794–0.995; AC + GnRH-a: aOR = 1.074, 95%CI 0.891–1.204) was only significantly higher, and early miscarriage rate (AC: aOR = 1.452, 95%CI 1.159–1.820; AC + GnRH-a: aOR = 1.317, 95%CI 0.929–1.868) was only significantly lower in NC compared to that of AC. While in older women (Table IV), except clinical pregnancy rates (AC: aOR = 0.901, 95%CI 0.804–1.010; AC + GnRH-a: aOR = 0.903, 95%CI 0.756–1.077) were comparable across groups, the incidences of live birth (AC: aOR = 0.811, 95%CI 0.718–0.916; AC + GnRH-a: aOR = 0.760, 95%CI 0.626–0.923) and ongoing pregnancy (AC: aOR = 0.881, 95%CI 0.719–0.915; AC + GnRH-a: aOR = 0.765, 95%CI 0.632–0.926) were significantly higher, and early miscarriage (AC: aOR = 1.358, 95%CI 1.141–1.655; AC + GnRH-a: aOR = 1.717, 95%CI 1.279–2.305) was significantly lower in NC compared to those of two AC groups.
|                        | NC (n=1783) | AC (n=6870) | $P_1$  | AC+GnRH-a (n=688) | $P_2$  |
|------------------------|-------------|-------------|--------|-------------------|--------|
| **Clinical pregnancy rate** |             |             |        |                   |        |
| Crude OR (95% CI)      | reference   | 1.019 (0.981, 1.213) | 0.109  | 1.205 (1.005, 1.446) | 0.044  |
| Adjusted OR (95% CI)   | reference   | 0.976 (0.870, 1.095) | 0.682  | 1.197 (0.988, 1.450) | 0.067  |
| **Ongoing pregnancy rate** |             |             |        |                   |        |
| Crude OR (95% CI)      | reference   | 0.982 (0.885, 1.090) | 0.737  | 1.087 (0.911, 1.296) | 0.356  |
| Adjusted OR (95% CI)   | reference   | 0.889 (0.794, 0.995) | 0.041  | 1.074 (0.891, 1.204) | 0.455  |
| **Live birth rate**    |             |             |        |                   |        |
| Crude OR (95% CI)      | reference   | 0.973 (0.877, 1.080) | 0.61   | 1.100 (0.922, 1.312) | 0.29   |
| Adjusted OR (95% CI)   | reference   | 0.894 (0.799, 1.001) | 0.051  | 1.111 (0.923, 1.337) | 0.267  |
| **Early miscarriage rate** |           |             |        |                   |        |
| Crude OR (95% CI)      | reference   | 1.410 (1.135, 1.751) | 0.002  | 1.300 (0.924, 1.830) | 0.132  |
| Adjusted OR (95% CI)   | reference   | 1.452 (1.159, 1.820) | 0.001  | 1.317 (0.929, 1.868) | 0.122  |

NC, natural cycle; AC, artificial cycle; GnRH-a, gonadotropin releasing hormone agonist

$P_1$: AC vs. NC, $P_2$: AC+GnRH-a vs. NC

$P < 0.05$ was considered as statistically significant
Table IV
Crude and adjusted ORs of different endometrial preparation protocols in older women.

|                      | NC (n=2110) | AC (n=4589) | $P_1$ | AC+GnRH-a (n=830) | $P_2$ |
|----------------------|-------------|-------------|-------|-------------------|-------|
| **Clinical pregnancy rate** |             |             |       |                   |       |
| Crude OR(95%CI)      | reference   | 1.003(0.904,1.113) | 0.957 | 0.879(0.747,1.036) | 0.124 |
| Adjusted OR(95%CI)   | reference   | 0.901(0.804,1.010) | 0.073 | 0.903(0.756,1.077) | 0.257 |
| **Ongoing pregnancy rate** |             |             |       |                   |       |
| Crude OR(95%CI)      | reference   | 0.904(0.809,1.009) | 0.072 | 0.754(0.631,0.901) | 0.002 |
| Adjusted OR(95%CI)   | reference   | 0.811(0.719,0.915) | 0.001 | 0.765(0.632,0.926) | 0.006 |
| **Live birth rate**  |             |             |       |                   |       |
| Crude OR(95%CI)      | reference   | 0.896(0.801,1.002) | 0.054 | 0.750(0.626,0.898) | 0.002 |
| Adjusted OR(95%CI)   | reference   | 0.811(0.718,0.916) | 0.001 | 0.760(0.626,0.923) | 0.006 |
| **Early miscarriage rate** |             |             |       |                   |       |
| Crude OR(95%CI)      | reference   | 1.317(1.091,1.590) | 0.004 | 1.685(1.271,1.235) | 0.000 |
| Adjusted OR(95%CI)   | reference   | 1.358(1.114,1.655) | 0.002 | 1.717(1.279,2.305) | 0.000 |

NC, natural cycle; AC, artificial cycle; GnRH-a, gonadotropin releasing hormone agonist

$P_1$: AC vs. NC, $P_2$: AC+GnRH-a vs. NC

$P<0.05$ was considered as statistically significant

**Discussion**

It is paramount to consider the appropriate preparation of the endometrium to receive the transferred embryos as the amount of FET cycles is increasing worldwide. Our study demonstrated that NC is superior to AC regarding pregnancy outcomes in general IVF population. To the best of our knowledge, our study is the first to evaluate the optimal endometrial preparation protocols in different age groups and concludes that there is a mild favor of AC + GnRH-a in younger women, but a remarkable priority of NC in older women.

There is no doubt that the two most important factors for a successful pregnancy are the availability of a good quality, euploid embryo, a receptive endometrium and synchrony of these factors. In FET, endometrium receptivity is achieved by dedicated endometrial preparation protocols, which can largely be
divided into natural and artificial cycles. In NC, usually solely menstrual cycle monitoring is performed without any pharmacological intervention prior to ovulation, which may be spontaneous (true NC) or triggered by HCG (modified NC). However, the timing of ovulation in NC may pose scheduling difficulties, and premature ovulation may occur and increase cancellation rates. In AC, exogenous hormone is administered to prepare the endometrium for embryo implantation, with exogenous to prime the endometrium, while progesterone to complete endometrial maturation. AC with GnRH-a pretreatment offers the most control over the timing and minimize the risk of premature ovulation, but the cycle is much more prolonged and expensive.

Several studies have compared NC and AC cycles in endometrial preparation, unfortunately the results have been conflicting. Two large scale meta-analyses comparing different cycle regimens of FET failed to show a superiority of one approach over the others in terms of reproductive outcomes, however, the majority of studies included were often of a low or very low quality of evidence as most were retrospective nature with limited sample size, and some fail to report important clinical outcomes, or had a poor reporting of study methods [6, 16]. A retrospective cohort study of 1265 cycles revealed that the implantation rate was significantly higher in NC, while there were no significant differences between the groups in the clinical pregnancy, ongoing pregnancy, live birth, and miscarriages rate [17]. El-Toukhy T and coworkers conducted a prospective randomized trial of 234 patients and found that using GnRH-a prior to exogenous steroid supplementation for endometrial preparation achieved significantly higher clinical pregnancy (24% vs 11.3%, OR 2.5, 95%CI 1.2–5.5) and live birth rates (20% vs 8.5%, OR 2.9, 95%CI 1.2-8). Our study suggests that in overall population, the incidence of live birth was higher in NC compared with AC without GnRH-a, but comparable to that of AC with GnRH-a. While the early miscarriage rate in NC was significantly lower than AC, either with or without GnRH-a pretreatment.

The decreased live birth and increased early miscarriage rate in AC might due to absence of the corpus luteum. Indeed, it has been reported that pregnancies achieved in the absence of a corpus luteum (CL) are at higher risk of hypertensive disorder, preeclampsia, and cesarean section delivery [9, 11, 18]. Relaxin is ~6 kDa peptide hormone secreted by CL and plays a key role in the transformation of the maternal circulation during early pregnancy especially before the “corpus luteal-placental shift” [19]. Absence of CL results in undetectable level of relaxin, as well as decreased levels of certain angiogenic and immunoregulatory factors, leading to insufficient cardiovascular adaptation and adverse pregnancy outcomes [20, 21]. The mechanism of GnRH-a pretreatment in improving pregnancy outcomes in AC is unclear. It is proposed that long GnRH-a treatment suppress untimely rises of progesterone levels during hormonal supplementation, which may advance the endometrium and hamper pregnancy outcomes. Besides, animal study suggested that GnRH agonist up-regulated the uterine expression levels of key receptivity markers including Hoxa10, Hoxa11, Lif and integrin b3 mRNA and protein, as well as increased the abundance of pinopodes in adenomyosis, therefore restoring endometrial receptivity [22].

Another intriguing finding of our study is that same endometrial protocol using in different age groups results in different reproductive outcomes. In younger women, there seems to be a mild favor of AC + GnRH-a protocol as the early miscarriage rate of NC was only significantly lower than that of AC, but
comparable to that of AC + GnRH-a. While the incidence of clinical pregnancy, ongoing pregnancy and live birth were both slightly higher in AC + GnRH-a than those in NC, although no reached statistical significance. Comparative proteomic analysis indicated that GnRH-a was associated with upregulation of cytoskeleton regulation and downregulation of energy metabolism on human endometrium. Younger patients present more vigorous metabolism than the older. It is possible that the downregulation of energy-metabolism proteins under GnRH-a treatment exerts a positive effect on the endometrium receptivity of younger women, but a negative effect on that of the older. In older women, the priority of NC to both AC groups was remarkable, as the ongoing pregnancy and live birth rate of NC is much higher, and early miscarriage rate was much lower in NC compared to AC, either with or without GnRH-a pretreatment. A recent study by Liu J and coworkers suggested that in women aged 38 years or over, the endometrial preparation protocols did not affect FET outcomes. However, the study was limited by the small sample size as only 457 cycles with advanced age included [23]. Advanced maternal age is an independent risk factor of thrombotic events [24]. Moreover, exogenous hormone increases the risk of vascular thrombosis [25]. Premature estradiol elevation lead to apoptosis of trophoblast and is associated with uteroplacental insuiciency, hence further worsen the pregnancy outcomes in older women using AC protocols [26].

Strengths and limitations

This study has several strengths. First, the large sample size of 16870 cycles enhances the statistical power. Second, the clinical and laboratory practices did not substantially change over the course of study, which should minimize the possible confounders associated with pregnancy outcome. Third, we adjusted for a number of potential confounders that might otherwise have biased the findings. Last but not least, this study has good representativeness as we avoid strict inclusion and exclusion criteria. This study is mainly limited by its retrospective nature. Besides, we could not control all the confounders. Finally, as all these data come from a single fertility center, multicenter study is warranted to verify the findings.

Conclusion

In conclusion, our study reveals that NC protocol was associated with lower early miscarriage late in overall population. There is a mild favor of GnRH-a cycles in younger women, while the priority of NC protocol is remarkable in the older. Maternal age should be a considerable factor when determine endometrial preparation method for FET.

Abbreviations

FET: Frozen-thawedembryo transfer; NC: natural cycle; AC: artificial cycle; COH: controlled ovarian stimulation; aOR: adjusted odds ratio; CL: corpus luteum

Declarations
Ethical Approval and Consent to participate

This study was approved by the Institutional Review Board of the Shenzhen Zhongshan Urology Hospital. The requirement of informed consent was waived due to the retrospective nature of the study.

Consent for publication

Not applicable.

Availability of supporting data

The datasets used and analysed during this study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This work was supported by National Key Research & Developmental Program of China (2018YFC1003900/2018YFC1003904) and Sanming Project of Medicine in Shenzhen (SZSM201502035). The funding body have not participated in the design of the study and collection, analysis, interpretation of data or in writing the manuscript.

Authors’ contributions

YZ and MLM supervised the entire study, including the design, procedures and revisions to the article. ZQZ analyzed the data and drafted the manuscript. SX and XJS took part in acquisition and analysis of data. HZZ and SRX took part in critical discussion and revision of the article. All authors read and approved the final manuscript.

Acknowledgements

We gratefully acknowledge all the staff of the fertility center in Shenzhen Zhongshan Urologic Hospital for their support and cooperation. We also thank Dr. Jiajun Su for the help with the statistical analysis.

References
1. Trounson A, Mohr L: Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature 1983, 305:707-709.

2. Ahuja KK, Macklon N: Vitrification and the demise of fresh treatment cycles in ART. Reprod Biomed Online 2020, 41:217-224.

3. Boynukalin FK, Turgut NE, Gultomruk M, Ecemis S, Yarkiner Z, Findikli N, Bahceci M: Impact of elective frozen vs. fresh embryo transfer strategies on cumulative live birth: Do deleterious effects still exist in normal & hyper responders? PLoS One 2020, 15:e0234481.

4. Biliangady R, Pandit R, Tudu NK, Kinila P, Maheswari U, Gopal IST, Swamy AG: Is It Time to Move Toward Freeze-All Strategy? - A Retrospective Study Comparing Live Birth Rates between Fresh and First Frozen Blastocyst Transfer. J Hum Reprod Sci 2019, 12:321-326.

5. Zhang W, Xiao X, Zhang J, Wang W, Wu J, Peng L, Wang X: Clinical outcomes of frozen embryo versus fresh embryo transfer following in vitro fertilization: a meta-analysis of randomized controlled trials. Arch Gynecol Obstet 2018, 298:259-272.

6. Groenewoud ER, Cantineau AE, Kollen BJ, Macklon NS, Cohlen BJ: What is the optimal means of preparing the endometrium in frozen-thawed embryo transfer cycles? A systematic review and meta-analysis. Hum Reprod Update 2013, 19:458-470.

7. Niu Z, Chen Q, Sun Y, Feng Y: Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis. Gynecol Endocrinol 2013, 29:1026-1030.

8. Park CW, Choi MH, Yang KM, Song IO: Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment. Clin Exp Reprod Med 2016, 43:169-173.

9. von Versen-Hoynck F, Schaub AM, Chi YY, Chiu KH, Liu J, Lingis M, Stan Williams R, Rhoton-Vlasak A, Nichols WW, Fleischmann RR, et al: Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum. Hypertension 2019, 73:640-649.

10. Dall’Agnol H, Garcia Velasco JA: Frozen embryo transfer and preeclampsia: where is the link? Curr Opin Obstet Gynecol 2020, 32:213-218.

11. Wang Z, Liu H, Song H, Li X, Jiang J, Sheng Y, Shi Y: Increased Risk of Pre-eclampsia After Frozen-Thawed Embryo Transfer in Programming Cycles. Front Med (Lausanne) 2020, 7:104.

12. Xiong F, Sun Q, Li G, Yao Z, Chen P, Wan C, Zhong H, Zeng Y: Association between the number of top-quality blastocysts and live births after single blastocyst transfer in the first fresh or vitrified-warmed IVF/ICSI cycle. Reprod Biomed Online 2020, 40:530-537.

13. Xiong F, Li G, Sun Q, Wang S, Wan C, Chen P, Yao Z, Zhong H, Zeng Y: Clinical outcomes after transfer of blastocysts derived from frozen-thawed cleavage embryos: a retrospective propensity-matched cohort study. Arch Gynecol Obstet 2019, 300:751-761.

14. Racowsky C, Vernon M, Mayer J, Ball GD, Behr B, Pomeroy KO, Wininger D, Gibbons W, Conaghan J, Stern JE: Standardization of grading embryo morphology. Fertil Steril 2010, 94:1152-1153.
15. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB: Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril 2000, 73:1155-1158.

16. Ghobara T, Gelbaya TA, Ayeleke RO: Cycle regimens for frozen-thawed embryo transfer. Cochrane Database Syst Rev 2017, 7:CD003414.

17. Cardenas Armas DF, Penarrubia J, Goday A, Guimera M, Vidal E, Manau D, Fabregues F: Frozen-thawed blastocyst transfer in natural cycle increase implantation rates compared artificial cycle. Gynecol Endocrinol 2019, 35:873-877.

18. Saito K, Kuwahara A, Ishikawa T, Morisaki N, Miyado M, Miyado K, Fukami M, Miyasaka N, Ishihara O, Irahara M, Saito H: Endometrial preparation methods for frozen-thawed embryo transfer are associated with altered risks of hypertensive disorders of pregnancy, placenta accreta, and gestational diabetes mellitus. Hum Reprod 2019, 34:1567-1575.

19. Weiss G, O’Byrne EM, Steinetz BG: Relaxin: a product of the human corpus luteum of pregnancy. Science 1976, 194:948-949.

20. Conrad KP, Graham GM, Chi YY, Zhai X, Li M, Williams RS, Rhoton-Vlasak A, Segal MS, Wood CE, Keller-Wood M: Potential influence of the corpus luteum on circulating reproductive and volume regulatory hormones, angiogenic and immunoregulatory factors in pregnant women. Am J Physiol Endocrinol Metab 2019, 317:E677-E685.

21. von Versen-Hoynck F, Narasimhan P, Selamet Tierney ES, Martinez N, Conrad KP, Baker VL, Winn VD: Absent or Excessive Corpus Luteum Number Is Associated With Altered Maternal Vascular Health in Early Pregnancy. Hypertension 2019, 73:680-690.

22. Guo S, Li Z, Yan L, Sun Y, Feng Y: GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. Drug Des Devel Ther 2018, 12:1621-1631.

23. Liu J, Zheng J, Lei YL, Wen XF: Effects of endometrial preparations and transferred embryo types on pregnancy outcome from patients with advanced maternal age. Syst Biol Reprod Med 2019, 65:181-186.

24. Armstrong EM, Bellone JM, Hornsby LB, Treadway S, Phillippe HM: Pregnancy-Related Venous Thromboembolism. J Pharm Pract 2014, 27:243-252.

25. Machin N, Ragni MV: Hormones and thrombosis: risk across the reproductive years and beyond. Transl Res 2020, 225:9-19.

26. Patel S, Kilburn B, Imudia A, Armant DR, Skafar DF: Estradiol Elicits Proapoptotic and Antiproliferative Effects in Human Trophoblast Cells. Biol Reprod 2015, 93:74.

Figures
Figure 1

Pregnancy outcomes of different endometrial preparation protocols in overall population.

Figure 2

Pregnancy outcomes of different endometrial preparation protocols in younger (A) and older (B) women.